Compare DTI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | CNTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 47.7M |
| IPO Year | 2021 | 2021 |
| Metric | DTI | CNTX |
|---|---|---|
| Price | $2.51 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 224.6K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,446,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.65 | $0.43 |
| 52 Week High | $4.69 | $3.62 |
| Indicator | DTI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.96 | 35.79 |
| Support Level | $2.24 | $0.43 |
| Resistance Level | $2.90 | $0.68 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 84.75 | 13.66 |
Drilling Tools International Corp is an oilfield services company that designs, engineers, and manufactures rental-focused tools used in onshore and offshore horizontal and directional drilling operations, as well as solutions across the well life cycle. It operates through two geographic segments: Western Hemisphere and Eastern Hemisphere. The Western Hemisphere, which generates the majority of revenue, provides downhole drilling tools and rental services for onshore and offshore operations across North America and Latin America, supported by service centers in the U.S. and Canada. The Eastern Hemisphere covers Europe, the Middle East, and Asia-Pacific, where the company offers drilling and well lifecycle solutions through international service centers across the EMEA and APAC regions.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.